Abstract. In clinical practice, glucocorticoids are often used with the aim of modulating the efficacy and toxicity of chemotherapeutic agents. However, how glucocorticoids modulate the pharmacological action of chemotherapeutic agents remains to be clarified. In this study, we generated glucocorticoid receptor (GR)-deficient rat-1 cells to investigate the role of GR in the regulation of cellular sensitivity to irinotecan hydrochloride (CPT-11). Treatment of wild-type rat-1 cells with dexamethasone (DEX) significantly enhanced the cytotoxic effect of CPT-11, whereas the treatment had little effect on the cytotoxicity of CPT-11 in GR-deficient cells. Topoisomerase-I activity in wild-type cells after concomitant treatment with DEX and CPT-11 was significantly lower than that after treatment with CPT-11 alone. DEX treatment also enhanced the inhibitory action of CPT-11 on the phosphatidylinositol 3-kinase-Akt signaling pathway in wild-type cells, accompanied by facilitating caspase-3 activity. These modulatory effects of DEX on the CPT-11-induced cytotoxicity were not observed in GR-deficient cells. Our present findings reveal the underlying mechanism by which GCs enhance the chemotherapeutic effect of CPT-11 and indicate the possibility that the dosage of CPT-11 could be reduced by the combination treatment with GCs, which may attenuate the adverse effect without decreasing anti-tumor activity.
Introduction
Irinotecan hydrochloride (CPT-11), [10-hydroxy-9- dimethylaminomethyl-(S)-camptothecin], a water-soluble camptothecin (CPT) analogue, has been shown to suppress the growth of small-cell and non-small-cell bronchogenic carcinoma, ovarian carcinoma, and myeloid leukemia (1) and has been approved for the treatment of ovarian cancer and small-cell lung cancer. However, the dosage and duration of CPT-11 treatment have been severely limited by serious adverse effects such as granulocytopenia and diarrhea. In cancer chemo-therapy, it is important to improve the quality of life (QOL) and to extend the survival time. Because the serious adverse effects often interrupt or stop the cancer treatment (2) , much effort has been made to improve the effect of chemotherapeutic agents and attenuate their toxicity (3) . For example, support treatments, such as administration of glucocorticoids (GCs) and 5-HT 3 -blockers, are often used with the aim of attenuating the adverse effects induced by a chemotherapeutic agent.
GCs are produced in the adrenal cortex under the strict control of the hypothalamus-pituitary-adrenal axis and play a key role in regulating diverse physiological processes such as metabolism, salt and water balance, cell proliferation, differentiation, inflammation, central nervous system, and immune responses (4) . Moreover, at pharmacological doses, a variety of GC analogs are used as an anti-inflammatory and / or immunosuppressive reagent (5) . We reported previously that GC has the ability to induce the expression of the Topoisomerase-I (Topo-I) gene, a nuclear target of CPT, in tumor cells (6) . Consequently, the expression of Topo-I in tumorbearing mice and the efficacy of CPT on the tumor were affected by the 24-h variation in circulating GC levels, suggesting that GCs act as a modulator of cellular sensitivity to CPT.
The GC signal is transduced via the glucocorticoid receptor (GR), which regulates the expression of a subset of genes in both a promoter and tissue-specific manner. Binding of GCs to GR causes it to dissociate from a cytoplasmic heterooligomer with heat shock proteins and induces its translocation into the nucleus. After entering the nucleus, GR rapidly binds as a homo-or heterodimer with GR to specific DNA enhancer elements, the glucocorticoid response elements (GREs), to change the transcriptional activity of their target gene (7, 8) . GR also influences the activities of other transcription factors, such as activating protein-1, nuclear factor-κB, and several signal transducers, and activators of transcription, through protein-protein interactions, possibly as a monomer (9) . Although these facts suggest that GR signal transduction influences the pharmacological effect of various types of drugs, it remains the role of GR in the regulation of cellular sensitivity to anti-tumor drugs remains to be clarified.
In this study, we found that the cytotoxic effect of CPT-11 was enhanced by the synthetic glucocorticoid analog dexamethasone (DEX). To explore the underlying mechanism, we generated GR-deficient rat-1 cells (GR's dominant negative form) by using a tetracycline repression system and investigated how GCs modulate the CPT-11-induced cytotoxicity.
Materials and Methods

Materials
CPT-11 was kindly supplied by the Yakult Co., Ltd. (Tokyo). The drug was dissolved in sterilized boiled water (80°C). DEX was purchased from Sigma Chemical Co. (St. Louis, MO, USA). For use, the compound was dissolved in a sterilized saline containing 1% dimethylsulfoxide.
Cell culture
Rat-1 fibroblast cells were supplied by the Cell Resource Center for Biomedical Research, Tohoku University (Sendai) and were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% FBS and kanamycin, penicillin, and streptomycin (0.05% each) in a humidified atmosphere of 95% air and 5% CO 2 at 37°C.
Experimental design
To generate conditional GR mutant clones, rat-1 fibroblast cells were cotransfected with a conditional expression construct of the mutated GR gene under the control of a tetracycline (tet)-repressible promoter. To investigate the influence of GCs on the cytotoxic effect of CPT-11, wild-type and GR-deficient cells were incubated in the medium containing various concentrations of CPT-11, in the presence or absence of DEX for 24 h. To explore the influence of GCs on the CPT-11-induced inhibition of Topo-I activity, wild-type and GR-deficient cells were treated with 50 μM CPT-11, in the presence or absence of 1000 nM DEX for 24 h. After incubation of cells with these drugs, Topo-I activity was determined by previous methods (10) . To explore the influence of GCs on the CPT-11-induced apoptotic signaling, wild-type and GR-deficient cells were treated with 50 μM CPT-11, in the presence or absence of 1000 nM DEX for 24 h. Protein abundance of phosphorylated Akt was measured by western blotting, and caspase-3 activity was determined using a fluorogenic substrate. The concentration of CPT-11 and its active metabolite SN-38 in wild-type and GR-deficient cells were determined at 5, 10, 30, and 60 min after the addition of the drug (50 μM CPT-11) into media. The concentrations of CPT-11 and SN-38 were also determined at the same times after the addition of both CPT-11 (50 μM) and DEX (1000 nM) into media.
Generation of GR-deficient cells
GR-deficient rat-1 cells were made by a previously described method (11) . The rat GR gene was isolated by degenerate RT-PCR of mRNA extracted from rat-1 cells. The sequences of the degenerate primers were 5'-CAAAGCCGTTTCACTGTCCA-3' and 5'-TGATCT CCAGGGACTCTCGT-3'. We screened a rat cDNA library (Stratagene, La Jolla, CA, USA) using the RT-PCR product as a probe. Several independent positive clones were sequenced and identified as full-length rat GR cDNAs. All plasmids were constructed by standard methods. The cDNAs deleting the DNA-binding domain (DBD; amino acids 440 -503) of GR (ΔDBD-GR) was generated by PCR. The ΔDBD-GR or full-length GR cDNA was cloned into the EcoRI site of pUHD10-3 to yield the tet-sensitive expression plasmid pUHD-GR (12) . The genomic structure of the GR clone was determined by PCR and partial sequencing. Rat-1 cells were transfected by electroporation with 30 μg each of the linearized plasmids. Zeo (Invitrogen, Carlsbad, CA, USA) was used at a final concentration of 1 mg / ml to select for stable transfectants. To suppress expression of the tet-responsive GR transgene, tet (Sigma, St. Louis, MO, USA) was added to the culture medium to a final concentration of 2 μg / ml. The expressions of full-length or mutated GR were confirmed by Southern blot and Western blot analysis as shown in Fig. 1 , B and C.
Southern blot analysis
To confirm the integration of the full-length GR or ΔDBD-GR expressing constructs into the genome of the host cells, each clone was analyzed by Southern blot hybridization. A 868-bp rat GR cDNA fragment, which did not contain the region coding DBD, was used as a probe.
Western blot analysis
The cells were solubilized with lysis buffer [50 mM Tris-HCl (pH 7.5), 0.5% Triton X-100, 3 mM EGTA, 12 mM β-glycerophosphate, 150 mM sodium chloride, 50 mM sodium fluoride, 1 mM sodium vanadate, 2 mM DTT, 1 mM phenylmethylsulfonyl fluoride, 1 mM aprotinin] and 30 min after, centrifuged at 5,000 rpm for 4 min at 4°C. The cell lysates containing 40 μg of total protein were mixed with 2 volumes of 2 × sample buffer [150 mM Tris-HCl (pH 6.8), 30% glycerol, 3% SDS, 0.24% bromophenol blue, 3% 2-mercaptoethanol] and heated at 100°C for 5 min. The protein concentrations were determined by Lowry's method (DC protein assay; BIO-RAD, Hercules, CA, USA). The cell lysates were applied to a 12% gradient polyacrylamide gel. The electrophoresed proteins were transblotted onto a PVDF membrane (Immobilon TM -P Transfer Membrane; Millipore, Billerica, MA, USA). After blocking, the membranes were reacted with antibodies against glucocorticoid receptor (recognize DBD), Akt, or phosphorylated-Akt (Cell Signaling Technology, Beverly, MA, USA). Thereafter, the membranes were incubated with an appropriate peroxidase-conjugated secondary antibody. The blots were visualized with ECLTM Western Blotting Reagents (Pierce Biotechnology, Inc., Rockford, IL, USA). The band intensity was quantified by using Kodak 1D image analysis software (Kodak, Tokyo).
Semi-quantitative RT-PCR analysis
Total RNA was extracted from rat-1 cells by using the RNeasy Mini Kit (QIAGEN, Hilden, Germany). The reverse transcription of RNA and cDNA amplification was performed with a one-step RT-PCR system (Invitrogen). The following oligodeoxynucleotide primers were used for Per1 (Genbank accession number: XM340822): 5'-GAATGAGGACGTCTTCACAC-3' and 5'-GCAGCTTTCCAAATACCTGA-3' and GAPDH (accession number: NM32599): 5'-GACCTCAACTAC ATGGTCTACA-3' and 5'-ACTCCACGACATACT CAGCAC-3'. The PCR product was electrophoresed through a 3% agarose gel including 0.2 μg / ml ethidium bromide and the gel was photographed under UV light (302 nm). The amount of RT-PCR products of each mRNA was quantified using Kodak 1D image analysis software and normalized against GAPDH.
Determination of cytotoxic effect
The cytotoxic effect of CPT-11 in rat-1 cells was determined by WST-8 assay (Cell Counting Kit-SF; Nacalai Tesque, Kyoto). In brief, 100 μl of rat-1 suspension at a density of 1 × 10 4 cell / ml was plated in a 96-well microplate. After incubating the microplate at 37°C in 5% CO 2 -95% air for 48 h, the plate was incubated at 37°C for 24 h with various concentrations of DEX and/ or CPT-11. After the incubation, 10 μl of the Cell Counting Kit solution was applied to each well and further incubated for 2 h at 37°C. Absorbance was measured at 450 nm using a microplate reader (Benchmark Microplate Reader, BIO-RAD) with a reference wavelength at 630 nm. The IC 50 values of CPT-11-induced cytotoxicity were estimated as the drug concentrations responsible for 50% growth inhibition as compared with cells incubated without drug. The values were calculated by fitting the data to following equation:
) , where Y is the inhibition rate of cell growth as compared with non-treatment groups, and X is the concentration of CPT-11 (μM). The IC 50 values were obtained from the results of triplicate determinations of at least three independent experiments.
Measurement of Topo-I activity
The activity of Topo-I in rat-1 cells was determined by the previously described method (13) . A sample of 5 × 10 6 cells was resuspended in 50 ml of phosphate buffer / 0.35% Triton X-100 and centrifuged at 5,000 rpm for 4 min at 4°C. The pellets were resuspended in 100 μl of extraction buffer [1 M Tris-HCl (pH 8.0) (20 μl), 5 M NaCl (70 μl), 14 M 2-mercaptoethanol (10 μl), 10 mg / ml bovine serum albumin (5 μl)/ H 2 O (895 μl)]. After 30 min, the cell suspension was centrifuged at 7,000 rpm for 15 min at 4°C. The supernatant was stored at −80°C. Topo-I activity was measured by the relaxation of supercoiled plasmid DNA using a Topo-I assay kit (TopoGEN, Inc., Columbus, OH, USA). The 20-μl assay mixture contained 16 μl H 2 O, 2 μl of 10× assay buffer [100 mM Tris-HCl (pH 7.9), 10 mM EDTA, 1.5 M NaCl, 1% bovine serum albumin, 1 mM spermidine, 50% glycerol], 1 μl of supercoiled plasmid substrate DNA (pUC19) {0.25 mg / ml TE buffer [10 mM Tris-HCl (pH 7.5), 1 mM EDTA]} and 1 μl of test sample. After 30 min at 37°C, the reactions were terminated by the addition of 5 μl of stop buffer / loading dye (5% sarkosyl, 0.125% bromophenol blue, 25% glycerol). The reaction product was digested with 1.25 mg / ml proteinase K (1 μl) at 37°C for 60 min. The relaxed plasmid substrate DNA and the reaction product with the super-coiled DNA in buffer without any enzyme fraction were used as markers. The samples were loaded onto a 0.8% agarose gel, and the gel was stained with ethidium bromide (1 mg / ml) for 30 min. The amount of DNA was quantified using a NIH image analysis program on a Macintosh computer. Topo-I activity was calculated from the ratios of relaxed DNA to total DNA (relaxed DNA / supercoiled DNA).
Determination of caspase-3 activity
The cells were lysed with caspase lysis buffer [10 mM HEPES (pH 7.4), 2 mM EDTA, 0.1% CHAPS, and 5 mM dithiothreitol]. The cell lysate (5 mg) was then incubated with 20 mM acetyl-L-aspartyl-L-glutamyl-Lvalyl-L-aspart-7-amino-4-methylcoumarin (DEVD-AMC; Peptide Institute, Osaka) containing caspase assay buffer [20 mM HEPES (pH 7.4), 10% glycerol, and 2 mM dithiothreitol] for 1 h at 37°C. The AMC released from the fluorogenic substrate was excited at 380 nm, and the emission was measured at 460 nm using a Hitachi fluorescence spectrophotometer, model F-2000 (Hitachi, Tokyo).
Determination of CPT-11 and SN-38 concentration in cultured cells
Cells were trypsinized and centrifuged at 15,000 rpm for 5 min at 4°C. The supernatants were used as samples. The samples (100 ng protein) were mixed with 0.1 mM diisopropyl fluorophosphate, internal standard compound (camptothecin: CPT; 0.125 or 1.25 μg/ ml, 25 μl), and methanol (375 μl), and the mixtures were centrifuged at 3,000 rpm for 10 min. After the centrifugation, the supernatant was separated and evaporated. The obtained residues were dissolved in 200 μl of a solution containing tetrahydrofuran / 50 mM KH 2 PO 4 and 5 mM heptanesulfonate (25:75, v / v), pH 2.0. The insoluble substance was removed by centrifugation at 10,000 rpm for 3 min. The solutions (20 or 50 μl) were injected into the HPLC system, which comprised a pump (LC-10AD Liquid Chromatograph; Shimadzu, Kyoto), a detector (RF-10A Spectrofluorometric Detector; Shimadzu), a chromatopac (C-R1B, Shimadzu), a guard column (TSK-GEL ODS-80TS, 5 μm, 3.5 mm I.D. × 15 mm; Toyo Soda, Tokyo), and an analytical column (TSK-GEL ODS-80TS, 5 μm, 4.6 mm I.D. × 150 mm; Toyo Soda). The mobile phases consisted of tetrahydrofuran / 50 mM KH 2 PO 4 and 5 mM heptanesulfonate (25:75, v/v, pH 4.0) for CPT-11 and tetrahydrofuran / 50 mM KH 2 PO 4 and 5 mM heptanesulfonate (32:68, v / v, pH 4.0) for SN-38. The peak areas were integrated using a data processor. The ranges of standard curve for CPT-11 and SN-38 were 15.625 -250 and 3.125 -100 ng / ml, respectively. The coefficient variation was less than 10%.
Statistical analyses
Analysis of variance (ANOVA) and Tukey's test were applied for the multiple comparison. Student's t-test was used for independent comparison between two groups. A probability level of P<0.05 was considered to be significant.
Results
DEX enhances the CPT-11-induced cytotoxicity in rat-1 cells Figure 1 shows the influence of DEX on the cytotoxic effect of CPT-11. Treatment of rat-1 fibroblast cells with CPT-11 resulted in significant reduction of cell viability in a dose-dependent manner (Fig. 1A) . Significant reduction of the cell viability was observed when the cells were treated with 50, 70, and 100 μM CPT-11 (P<0.05 for 50 μM, P<0.01 for 70 μM, and P<0.01 for 100 μM). The IC 50 value of the cytotoxic effect was 55 mM. DEX dose-dependently enhanced the CPT-11-induced cytotoxicity (Fig. 1B) . Significant enhancement was observed when the CPT-11-treated cells were incubated with 100 and 1000 nM DEX (P<0.05 for 100 nM and P<0.01 for1000 nM). These results suggest that DEX has the ability to enhance the cytotoxic effect of CPT-11.
Generation of GR-deficient rat-1 cells
DEX exerts its effects via activation of GR, which then interacts with the GR response elements (GREs) of various genes (7, 8) . We thus tried to generate GRdeficient rat-1 cells to investigate the underlying mechanism by which DEX enhances the cytotoxic effect of CPT-11. To generate conditional GR mutant clones, we cotransfected with a conditional expression construct of the mutated GR gene under the control of a tetrepressible promoter and a tet-repressible transactivator-containing zeocin (zeo)-resistance cassette into rat-1 cells. We selected zeo-resistant colonies and identified several clones carrying these constructs integrated at random sites in the genome. Figure 2A shows the strategy for generation of the GR-deletion mutant. To generate GR-mutant clones, we selected amino acids for overexpression; full-length GR (amino acid 1-793) and deletion of DNA binding domain (amino acid 440-503) mutant (ΔDBD-GR). The results of southern hybridization analyses confirmed introduction of these constructs to the genome (Fig. 2B) . The dark bands around the wild-type GR indicated the incorporation of constructs coding full-length GR or ΔDBD-GR into the genomic DNA. Furthermore, the results of western blot analyses also showed the expression of full-length and partially deleted form of GR protein in rat-1 cells (Fig. 2C) . It has been reported that brief exposure of rat-1 cells to DEX rapidly induces the expression of Period1 (Per1) gene (11) . Treatment of wild-type and full-length GR expressing cells with DEX for 2 h resulted in a 7-to 9-fold increase over the basal levels of Per1 mRNA (Fig. 2D) . On the other hand, after DEX treatment, the mRNA levels of Per1 in ΔDBD-GR expressing cells were significantly lower than those in wild-type and full-length GR expressing cells. These results revealed that ΔDBD-GR expressing cells are deficient in the function of GR. We therefore decided to use these cells for evaluating as GR-deficient cells. Figure 3 shows the influence of GR deficieny on the DEX-modulated cytotoxic effect of CPT-11. The IC 50 values for the cytotoxic effect of CPT-11 on wild-type cells were decreased by DEX treatment. Significant decreases in the IC 50 values for the cytotoxic effect of CPT-11 were found in the cells treated with 100 and 1000 nM DEX (P<0.05 and P<0.01, respectively) ( Fig. 3: left panel) . A similar result was also observed when full-length GR-expressing cells were treated concomitantly with CPT-11 and DEX (Supplementary Fig. 1 : available at online version only). On the other hand, concomitant treatment of GR-deficient cells with CPT-11 and DEX had little effect on the IC 50 values for the cytotoxic effect of CPT-11 ( Fig. 3: right panel) . The growth rate and viability of GR-deficient cells were not significantly different from those of wild-type cells (data not shown). It is thus unlikely that the inability of DEX to enhance the cytotoxic effect of CPT-11 on GRdeficient cells is due to a change in the cell viability.
DEX fails to enhance the CPT-11-induced cytotoxicity in GR-deficient cells
As reported previously (14) , the Topo-I activity in wild-type cells was significantly decreased by CPT-11 treatment (P<0.05) (Fig. 4: left panel) . The inhibitory effect of CPT-11 on the Topo-I activity was further enhanced by DEX (P<0.05). By contrast, the enhancing effect of DEX on the CPT-11-induced inhibition of Topo-I activity was not observed in GR-deficient cells (Fig. 4: right panel) . These results suggest that deficieny in the function of GR leads to the inability of DEX to enhance the CPT-11-induced inhibition of Topo-I activity. 
DEX fails to enhance the CPT-11-induced apoptotic signaling in GR-deficient cells
It has been reported that CPT-11 can induce the caspase-3 activity through down-regulation of the phosphatidylinositol 3-kinase [PI(3)K]-Akt signal pathway, which leads induction of apoptotic cell death (15) . In wild-type cells, the protein abundance of phosphorylated Akt (p-Akt) was obviously decreased by treatment of the cells with DEX or CPT-11 ( Fig. 5A: left panel, lanes 2  and 3) . The phosphorylated protein levels were further decreased by concomitant treatment with DEX and CPT-11 (lane 4). On the other hand, although the protein abundance of p-Akt in DEX-treated GR-deficient cells were not obviously different from those in vehicletreated GR-deficient cells (Fig. 5A: right panel, lanes 5  and 6) , the phosphorylated protein levels were decreased by treatment with CPT-11 (lane 7). However, the CPT-11-induced decrease in p-Akt protein levels was not affected by DEX treatment (lane 8).
The caspase-3 activity in wild-type cells after DEX treatment was not significantly different from those after vehicle treatment (control), whereas treatment of the cells with CPT-11 resulted in a significant increase in the caspase-3 activity (P<0.05) (Fig. 5B: left panel) . The CPT-11-induced caspase-3 activity was further enhanced by treating cells with DEX (P<0.05). On the other hand, although the caspase-3 activity in GR-deficient cells was significantly increased by treatment with CPT-11 (P<0.05) (Fig. 5B: right panel) , the CPT-11-induced caspase-3 activity was not affected by DEX treatment. These result suggest that the inhibitory action of DEX on the PI(3)K-Akt signal has an additive effect on the CPT-11-induced activation of the apoptotic signaling pathway.
DEX fails to modulate the pharmacokinetics of CPT-11 in rat-1 cells in GR-deficient cells
In the final set of experiments, we investigated whether the pharmacokinetics of CPT-11 in the cultured rat-1 cells was modulated by DEX treatment. In the absence of DEX, the concentration of CPT-11 in wildtype cells was gradually increased and reached about 8.0 μg / mg protein at 60 min after addition of the drug into media (Fig. 6A: left panel) . The concentration of CPT-11 in wild-type cells was further increased when the cells were treated with both CPT-11 and DEX. At 30 and 60 min after the initiation of drug treatment, the concentration of CPT-11 in wild-type cells treated concomitantly with CPT-11 and DEX was significantly higher than those in the cells treated with CPT-11 alone (P<0.05 for 30 min and P<0.01 for 60 min). Similarly, the concentration of SN-38, the active metabolite of CPT-11, in wild-type cells was also gradually increased after addition of CPT-11 into media (Fig. 6B: left panel) . At 60 min after the initiation of drug treatment, the concentration of SN-38 in wild-type cells treated concomitantly with CPT-11 and DEX was significantly higher than that in the cells treated with CPT-11 alone (P<0.05). In contrast to these observations, the concentrations of CPT-11 and SN-38 in GR-deficient cells treated concomitantly with CPT-11 and DEX were not significantly different from those in the cells treated with CPT-11 alone (Fig. 6A : right panel and Fig. 6B: right panel) . These results suggest that DEX can enhance cellular accumulation of CPT-11 and its active metabolites. The pharmacokinetic modulation of CPT-11 may also contribute to the DEX-enhanced cytotoxic effect of CPT-11. 
Discussion
Although the relevance of GCs to the cytotoxic effect of CPT-11 (6, 16) has been suggested, little is known about how the Topo-I-dependent drug action is modulated by GC and its receptor signaling. We thus generated GR-deficient cells (ΔDBD-GR cells) to explore the role of GR signaling in the regulation of cellular sensitivity to CPT-11. DBD amino acids of GR are important for its binding ability to the DNA sequence in their target genes. In fact, cells with a deletion of the DBD amino acids failed to express Per1 in response to DEX stimuli. We therefore decided to use ΔDBD-GR cells as GR-deficient cells. Although there was no significant difference in the cytotoxic effect of CPT-11 on wild-type and GR-deficient cells, the cytotoxicity in wild-type cells, but not in GR-deficient cells, was significantly enhanced by DEX treatment.
There are several mechanisms by which DEX enhances the cytotoxic effect of CPT-11. The cytotoxicity of CPT-11 is partly caused by inhibition of cell growth. One possible mechanism of DEX-enhanced cytotoxicity of CPT-11 could be explained by augmenting its inhibitory action on the growth of cells. A mechanism underlying the inhibitory action of CPT-11 on cell growth is the repression of the DNA synthesis by stabilizing the complex of Topo-I and DNA (14, 17) . Topo-I induces transient single-strand DNA breaks that lead to relaxation of supercoiled DNA, which is an essential step for DNA replication and RNA transcription. CPT-11 interferes with Topo-I activity and stabilization of the covalent complex between Topo-I and DNA, which prevents the religation of enzyme-linked single-strand DNA breaks (14) . DEX treatment enhanced the CPT-11-induced inhibition of Topo-I activity in wild-type cells, but the enhancement effect was not observed in GR-deficient cells. This may partly account for the inability of DEX to modulate the CPT-11-induced cytotoxicity in GR-deficient cells and indicates a mechanism by which DEX enhances the cytotoxic effect of CPT-11.
On the other hand, the cytotoxic effect of CPT-11 is also caused by the promotion of apoptotic cell death through down-regulation of the PI(3)K-Akt survival pathway (15) . The serine / threonine kinase Akt is a downstream effector of PI(3)K that is recognized as the major mediator of survival signals that protect cells from undergoing apoptosis (18) . In this study, we found that the CPT-11-induced decrease in p-Akt levels in wild-type cells was enhanced by DEX treatment, and the treatment also enhanced the CPT-11-induced caspase-3 activity. However, such modulatory action of DEX was not observed in GR-deficient cells. This may also account for the inability of DEX to modulate the CPT-11-induced cytotoxicity in GR-deficient cells. Akt is activated in response to PI(3)K and their lipid products such as phosphatidylinositol 3,4,5-triphosphate (PIP 3 ) (19) . The lipid products can bind to the pleckstrin homology domain of Akt, causing its translocation to the membrane, which accelerates the phosphorylation of Akt by 3-phosphoinositide-dependent protein kinase 1 (PDK1) and other protein kinases (20) . PI(3)K is formed as heterodimer containing a p85 regulatory subunit and a p110 catalytic subunit (20) . Two closely related p85 isoforms, p85α and p85β, have been characterized. It has been suggested that GCs are able to induce the expression of p85α and increase its cellular abundance. Excessively expressed p85α competes with the p110 / p85 PI(3)K heterodimer, thereby inhibiting translocation of the p110 catalytic subunit to the membrane surface and retarding PI(3)K activity (21) . We also found that treatment of wild-type rat-1 cells with DEX induced the expression of p85α, accompanied by decrease in p-Akt protein levels ( Supplementary Fig. 2 : available at online version only). However, the inductive effect of DEX was not observed in GR-deficient cells. In consequence, DEX treatment seemed to suppress the PI(3)K-Akt signaling by increasing cellular abundance of p85α, which might enhance the CPT-11-induced caspase-3 activity in wild-type cells. The inability of DEX to induce the expression of p85α would likely fail to enhance the CPT-11-induced caspase-3 activity in GR-deficient cells.
In general, cytotoxicity of chemotherapeutic agents is caused not only by the sensitivity of cells to drugs but also by their pharmacokinetics. The concentration of CPT-11 in wild-type cells was significantly increased by DEX treatment. The treatment also increased the amount of SN-38 in the cells. The enhancement effects of DEX on CPT-11 accumulation in wild-type cells could be considered to reflect its modulatory action on the CPT-11-induced inhibition of Topo-I activity and PI(3)K-Akt signaling. It is known that P-glycoprotein (P-gp) serves as an efflux pump of CPT-11 as well as DEX (22, 23) . In consequence, during the concomitant treatment with DEX and CPT-11, DEX may competitively interfere with CPT-11 for transporting by P-gp, resulting in the accumulation of CPT-11 and its metabolite SN-38 in wild-type cells. The higher accumulation may also enhance the cytotoxic effect of CPT-11 through augmenting the inhibition of Topo-I activity and down-regulation of the PI(3)K-Akt survival pathway. On the other hand, during the treatment with CPT-11 alone, the concentration of the drug in GR-deficient cells was lower than that in wild-type cells, and treatment of GR-deficient cells with DEX had little influence on cellular concentration of CPT-11. The GC signal has been shown to up-or down-regulate the expression of P-gp (24) , but the bidirectional regulation of P-gp expression by the GC signal is dependent on the type of cell. It is thus possible that deficiency in the function of GR alters the levels of P-gp expression. The alteration may accelerate efflux of CPT-11 from GR-deficient cells. Further studies are required to investigate this hypothesis.
Our present findings revealed the ability of DEX to modulate the cellular sensitivity to the chemotherapeutic agent CPT-11 and would provide a clue to clarify the role of GR in the DEX-induced modulation of the cytotoxic effect of CPT-11. The concentrations of DEX (100 -1000 nM) used in this study were 4 -40 times higher than the concentration of this drug used in humans. Although such a high concentration of DEX may cause adverse effects, the present findings indicate the possibility that the dosage of CPT-11 could be reduced by the combination treatment with GCs, which may attenuate the adverse effect without decreasing anti-tumor activity.
